

## The Statistics Need to Change



### Massive scale of mental illness in Australia – and getting worse

- 1 in 5 adults with chronic mental illness
- 1 in 8 on antidepressants/1 in 4 older people/1 in 30 children (18% increase in 5 years, 95% in 15 years)
- Over 45% of Australians will experience a mental illness in their lifetime

*Common mental illnesses are depression, post-traumatic stress disorder and anxiety disorders.*

## Current Treatments

- **Depression:** Only 35% of sufferers experience **remission** from pharmacotherapy (anti-depressants) and/or psychotherapy
- **PTSD:** Only 20-30% of sufferers show some **response** to pharmacotherapy and only about 50% respond to any treatments. **Remission** rates are as low as 5%

*A “more of the same” approach is not going to solve the problem.*

## A New Paradigm for the Future



Both psilocybin-assisted psychotherapy for major and treatment resistant depression, as well as MDMA-assisted psychotherapy for PTSD have been granted “**Breakthrough Therapy Designation**” by the Food and Drug Administration (FDA) in the United States to fast-track the approval process. **Very safe in a medically controlled environment, non-addictive** and no increase in risk for mental illness. The psychedelic-assisted therapy sector is estimated to be valued at up to \$US200B in the future.

## Backed by International Clinical Research


Remarkable clinical results for an increasing number of treatment indications including depression, PTSD, end-of-life anxiety, OCD, anorexia, addiction and dementia. Over 150+ current or completed trials.

Most effective treatments for mental illness show effect sizes using the Cohen’s D scale of around  $d=0.5$  (0.2=‘small’; 0.5=‘medium’; 0.8=‘large’ treatment benefit)

Antidepressants (SSRI’s) for depression:  $d=0.3$   
 Psilocybin for depression:  $d=2.0-3.1$   
 Psilocybin for end-of-life distress:  $d=0.8-1.6$   
 Psilocybin for alcoholism:  $d=1.2-1.4$   
 MDMA for PTSD:  $d=1.17-1.24$

Psilocybin and MDMA-assisted therapies are showing remission rates of 60-80% after just 2-3 doses for complex mental health disorders.

*Increased communication between brain networks  
(based on fMRI scans)*



Source: The Royal Society, Nature Reviews Neuroscience 10, 186–198

## Mind Medicine Australia


*Our mission is to expand the treatment paradigm in Australia for mental illness, by developing the ecosystem for effective, evidence-based treatments, for all Australians.*

Awareness and Knowledge Building

International Summit November 2021

Access to New Medically Approved Therapies

Development of Regulatory & Patient Access Pathways



Therapist and Clinician Education

Professional Development Programs

Asia-Pacific Centre for Emerging Mental Health Therapies

Applied Research & Prototype Clinic

## Our Mission

Mind Medicine Australia (MMA) is a registered charity that seeks to alleviate the suffering caused by mental illness in Australia through **expanding the treatment options available** to medical practitioners and their patients. We are focused on the development of **safe and effective psychedelic-assisted therapies** to cure a range of mental illnesses.

MMA was founded in 2019 by social entrepreneurs Tania de Jong AM and Peter Hunt AM. We are also supported by an outstanding Board, Ambassadors and an Advisory Panel of **over 70 local and international experts** in medicine, psychiatry, psychology, pharmacology, research, science, ethics, law, policy,

## Our Progress

- 120+ webinars, screenings and special events attracting 20,000+ participants globally
- 200+ regular donors
- 27+ local Chapters around Australia and New Zealand with 600+ members and growing
- 20+ world leading speakers at our International Summit on Psychedelic Therapies for Mental Illness in November 2021 with 150+ partner organisations
- MMA successfully applied to the TGA to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Medicines) to Schedule 8 (Controlled Medicine), making Australia the first country to recognise MDMA and psilocybin as medicines for treatment resistant patients with depression and PTSD
- Launched our Certificate in Psychedelic-Assisted Therapies with 100+ therapists in training annually
- Development of treatment protocols, standard operating procedures and training manuals

## Your Donation Supports



### Professional Development Program

This includes our Certificate in Psychedelic-Assisted Therapies programme, as well as shorter workshops to prepare mental health professionals for the future.



### Awareness and Knowledge Building

We organise educational events, film screenings, conferences and also have local chapters open to the public.



### Access to Medically Approved Therapy

We promote changes in legislation, promote legal and ethical frameworks, provide psychological support services, develop clinical rollouts and medicine manufacturing capabilities.



### Engagement with University sector and novel research

Engagement with universities to promote research, development and economic analysis and rollout plans.



### Supporting those who cannot afford treatments

We are setting up a special Patient Support Fund to receive donations from large to small philanthropists, and hopefully governments around Australia, to support those who cannot afford the full costs of treatments.

**With your support, we can prevent suicide and suffering and develop a better paradigm for mental illness treatments. All donations over \$2 are fully tax-deductible.**

**Please donate now at: [mindmedicineaustralia.org.au/donate](https://mindmedicineaustralia.org.au/donate)**